Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1779
http://purl.obolibrary.org/obo/NCIT_C1779
|
|---|---|
| Preferred Name | Atrasentan Hydrochloride |
| Definitions |
The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation. |
|---|---|
| prefLabel | Atrasentan Hydrochloride
|
| label | Atrasentan Hydrochloride
|
| PDQ_Closed_Trial_Search_ID | 38333
|
| code | C1779
|
| Has_Target | |
| prefixIRI | NCIT:C1779
|
| in_subset |
See more
See less
|
| Display_Name | Atrasentan Hydrochloride
|
| Preferred_Name | Atrasentan Hydrochloride
|
| FDA_UNII_Code | E4G31X93ZA
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C29H38N2O6.ClH
|
| Maps_To | Atrasentan Hydrochloride
|
| CAS_Registry | 195733-43-8
|
| NSC Number | 720763
|
| NCI_Drug_Dictionary_ID | 38333
|
| Legacy Concept Name | Atrasentan
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38333
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0387926
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |